Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285253 · ClinicalTrials.gov registry record · Phase 1
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
A Phase 1 study, sponsored by Miromatrix Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06285253 is a Phase 1 study that has completed, run by Miromatrix Medical. The registered enrollment target is 10 participants.
The verdict
NCT06285253, a Phase 1 study, has completed, sponsored by Miromatrix Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.
Interventions
- COMBINATION_PRODUCT miroliverELAP treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-10-05 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06285253
The ClinicalTrials.gov registry entry for NCT06285253 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Miromatrix Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which miroliverELAP treatment is the first listed.
NCT06285253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06285253 about?
NCT06285253 is a clinical study titled "miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial". The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver gra...
What is the current status of trial NCT06285253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-10-05. Estimated completion is 2026-01-22.
What interventions are being tested in trial NCT06285253?
The interventions under investigation include: miroliverELAP treatment (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06285253?
This trial is sponsored by Miromatrix Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.